Cognitive impairment is a major secondary consequence of Type II diabetes mellitus. The present investigation is designed to enhance the efficacy of an antidiabetic drug (Saxagliptin/SXG) against diabetes-induced cognitive impairment in rats. SXG has limited blood-brain barrier (BBB) permeability due to its hydrophilic nature. Phytochemical-based carboxylic acid conjugates enhance the lipophilicity and anti-oxidant properties of the drugs. Virtually SXG was conjugated with 10 different carboxylic acids and evaluated for drug-likeness, pre-ADMET, Molecular docking, and HUMO-LUMO study. Based on the molecular weight, log P value, docking score, and toxicity profile; three carboxylic acids were selected. Gallic acid (GA), Isonicotinic acid (INA), and Caffeic acid (CA) conjugates of SXG were synthesized and characterized by FTIR, and NMR studies. Diabetes-induced cognitive impairment was induced in the rats by administration of STZ, 45 mg kg-1 i.p. Learning and memory were evaluated by assessing spontaneous alternation behavior (SAB), number of correct responses, and transfer latency using Y-maze, radial arm maze, and elevated plus maze respectively. The antioxidant activity, nitrite levels, acetylcholine esterase level, and Aβ42 content in the rat brain was also evaluated. Histopathology of the hippocampal area was also done. The carboxamides of SXG have improved the efficacy of SXG against diabetes-induced cognitive impairment. This neuroprotective effect of carboxamides of SXG may be attributed to anti-oxidant activity, cholinergic activity, and anti-amyloid β activity.